Friday, November 17, 2017

FDA Expands Indication of Electric Stimulation Device to Treat Opioid Withdrawal Symptoms

The Food and Drug Administration (FDA) has approved the use of an electric stimulation device to help to reduce the symptoms of opioid withdrawal, marking the first time a device has been indicated for withdrawal symptoms.

The NSS-2 Bridge is a small device placed behind the patient’s ear that emits electrical pulses to stimulate cranial nerves. These stimulations provide relief from common withdrawal symptoms during the first few days of drug abstinence; these include sweating, tremors, stomach problems, insomnia, and joint pain.

“Given the scope of the epidemic of opioid addiction, we need to find innovative new ways to help those currently addicted live lives of sobriety with the assistance of medically assisted treatment,” said FDA Commissioner Scott Gottlieb, M.D., in a press announcement. “While we continue to pursue better medicines for the treatment of opioid use disorder, we also need to look to devices that can assist in this therapy.”

The FDA marketing approval was granted based on an open-label pilot study of the effects of the nerve stimulator on 73 patients undergoing opioid physical withdrawal. The study found that the average clinical opiate withdrawal scale (COWS) scores of the participants dropped by about 63% after 20 minutes of use, and 85% after 60 minutes. After five days of use, 64 of the 73 participants (88%) successfully transitioned to medication-assisted treatment (MAT). Successful transition to MAT was defined as “those who returned to the clinic and received their first dose of maintenance medication,” the study authors noted in a report published in March in the American Journal of Drug and Alcohol Abuse.

The FDA reviewed the NSS-2 Bridge device through the de novo premarket review pathway, a regulatory pathway that fast-tracks low- to moderate-risk devices that are novel and for which there is no legally marketed predicate device to which the device can be compared. The device was developed by Innovative Health Solutions Inc., and was cleared by the FDA in 2014 for use in acupuncture.

To read more about this topic, see the Psychiatric News article “FDA Clears First Prescription-Based ‘Digital Therapeutic.”

Thursday, November 16, 2017

APA, Five Other Medical Groups Voice Opposition to Senate Proposal to Remove Individual Mandate

Repeal of the mandate under the Affordable Care Act (ACA) to buy health insurance is likely to raise premiums and increase the number of uninsured Americans, APA and five other medical specialty organizations said in a statement released today responding to provisions in the Senate tax reform bill that would eliminate the mandate.

“The Congressional Budget Office (CBO) estimates that repeal of the individual mandate will result in 13 million people becoming uninsured by 2027,” APA and the five other groups said. “Furthermore, repealing the mandate will increase premiums and destabilize the individual and small group markets.”

The five other organizations are the American Academy of Family Physicians, the American Academy of Pediatrics, the American College of Physicians, the American College of Obstetricians and Gynecologists, and the American Osteopathic Association. Together, they represent more than 560,000 physicians and medical students nationwide.

The so-called “individual mandate” requires individuals not otherwise covered by health insurance to buy insurance in the ACA health exchanges or pay a tax penalty. Advocates say that without the mandate to buy health insurance, only the sick would enroll, causing adverse selection and destabilization of insurance markets.

“Our members are the nation’s frontline physicians, providing care to individuals and families in communities large and small, urban and rural,” the groups stated. “They see each day the inherent value of having health care coverage. Health care coverage is the gateway to prevention and wellness and a guardrail in the event of a major health event. Having health care coverage and a continuous relationship with a physician are the two factors that have been proven the world over to increase quality and decrease cost.

“Additionally, increased access to affordable health care coverage is a major reason that bankruptcies related to health care have decreased significantly over the past five years. Health care coverage provides financial security to millions of people and protects them in the most challenging times of their life, especially those that have pre-existing conditions and conditions that require a high intensity of care over their lifetime.

“Our organizations oppose provisions in the Senate tax reform proposal that would repeal policies requiring individuals to purchase health care coverage,” they continued. “Our health care system needs improvements, and our organizations stand ready to work with the Senate to identify bipartisan and impactful reforms that will ensure a robust and competitive health care market. However, according to the Congressional Budget Office, repeal of the individual mandate in this form, absent additional reforms that would stabilize the insurance market, has the potential to raise health insurance premiums by a projected 20 percent and increase the number of uninsured Americans.”

(Image: iStock/Tupungato)

Wednesday, November 15, 2017

Naltrexone, Buprenorphine-Naloxone Found Equally Effective in OUD Patients Who Initiate Treatment

Extended-release naltrexone and sublingual buprenorphine-naloxone appear to be equally safe and effective at preventing opioid relapse in patients with opioid use disorder (OUD). However, it can be harder to initiate patients actively using opioids on naltrexone (due to required detox period) than buprenorphine-naloxone. These two findings were reported in a study published yesterday in The Lancet.

“Both medications are effective treatments for opioid use disorders versus counseling-only approaches or compared to placebo. What is now clear is how similar the outcomes are for those initiating treatment with either medication,” Joshua D. Lee, M.D., M.Sc., of NYU School of Medicine said in a press release. “Patients wanting naltrexone but who are unable to complete detox should be encouraged to start an agonist-based treatment like buprenorphine.”

Naltrexone (an opioid μ-receptor antagonist) differs from buprenorphine both in terms of induction and ongoing care. The medication cannot be initiated until patients are fully detoxified without risking precipitated withdrawal, but once initiated, naltrexone produces no opioid-like effects and no physiological dependence. In contrast, buprenorphine (a partial agonist) can be initiated as soon as patients are in mild-to-moderate withdrawal. Unlike naltrexone, buprenorphine maintains physiological opioid dependence, and withdrawal is likely to occur on discontinuation.

Lee and colleagues randomly assigned 570 patients with OUD to receive monthly injections of extended-release naltrexone (brand name Vivitrol) or daily buprenorphine-naloxone (brand name Suboxone) for 24 weeks. Study participants were 18 years or older and had used non-prescribed opioids in the past 30 days. Unlike patients in the buprenorphine-naloxone group, who received medication shortly after randomization, those assigned to naltrexone had to complete detoxification before receiving the first injection of medication. Detoxification was defined as not using an opioid for three or more days, having urine that tested negative for opioids, and having a negative naloxone challenge.

As expected, fewer patients successfully initiated naltrexone compared with buprenorphine/naloxone (72% versus 94%). Of the 474 patients who successfully began treatment, the proportion of opioid-relapse events over the course of the study was similar (52% for the naltrexone group versus 56% for the buprenorphine/naloxone group). The proportion of participants reporting adverse events and serious adverse events did not differ between the groups, with the exception of reactions at the injection site of naltrexone, all of which were of minor to moderate severity.

“Studies show that people with opioid dependence who follow detoxification with no medication are very likely to return to drug use, yet many treatment programs have been slow to accept medications that have proven to be safe and effective,” Nora D. Volkow, M.D., director of the National Institute on Drug Abuse, said in a press release. “These findings should encourage clinicians to use medication protocols, and these important results come at a time when communities are struggling to link a growing number of patients with the most effective individualized treatment.”

For related information, see the Psychiatric News PsychoPharm article “Psychiatrists Discuss Risks, Benefits of Medications for Opioid Use Disorder.”

(Image: iStock/monkeybusinessimages)

Tuesday, November 14, 2017

FDA Approves Abilify Pill With Embedded Digital Sensor to Track Ingestion

The Food and Drug Administration (FDA) on Monday approved Abilify MyCite—aripiprazole tablets with a sensor that digitally tracks if patients have ingested their medication.

The product is approved for the treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder, and for use as an add-on treatment for depression in adults.

According to an FDA press release, the system works by sending a message from the pill’s sensor to a wearable patch. The patch transmits the information to a mobile application so that patients can track the ingestion of the medication on their smartphone. Patients can also permit their caregivers and physician to access the information through a web-based portal.

“Being able to track ingestion of medications prescribed for mental illness may be useful for some patients,” Mitchell Mathis, M.D., director of the Division of Psychiatry Products in the FDA’s Center for Drug Evaluation and Research, said in the FDA press release. “The FDA supports the development and use of new technology in prescription drugs and is committed to working with companies to understand how technology might benefit patients and prescribers.”

The FDA noted in its release that the ability of the product to improve patient compliance with their treatment regimen has not been shown. Abilify MyCite should not be used to track drug ingestion in “real-time” or during an emergency because detection may be delayed or may not occur, the agency added.

The “digital health feedback system” (DHFS) has attracted the attention of clinician researchers interested in novel ways to improve medication adherence among patients with schizophrenia and bipolar disorder. In 2010, John Kane, M.D., and colleagues at Zucker Hillside Hospital and Massachusetts General Hospital partnered with Proteus Digital Health Inc.—the manufacturer of the DHFS technology—to characterize the feasibility and safety of the system in patients with bipolar disorder and schizophrenia. A principle concern at the outset was whether patients who may have paranoid or persecutory delusions would be amenable to using a device allowing others to monitor their behavior.

In a paper published in the Journal of Clinical Psychiatry (June 2013), Kane and colleagues found that of the 27 patients with schizophrenia or bipolar disorder who completed the study, none experienced a worsening of psychosis attributable to use of the DHFS, 19 found the DHFS concept easy to understand, and 24 said they believed the technology could be useful to them. (For the purposes of the study, the pill with the embedded DHFS was not pharmacologically active.) 

For related information, see the Psychiatric News article “Technologies Promise to Aid Medication Adherence, but Effectiveness Varies.”

Monday, November 13, 2017

ADHD Medication Use During Pregnancy Poses Modest Birth Risks

The use of attention-deficit/hyperactivity disorder (ADHD) medications during pregnancy can modestly increase the risk of some negative birth outcomes, according to a study published Friday in Pediatrics

Ulrika Nörby, Ph.D., of Lund University in Sweden and colleagues found that infants exposed to ADHD medications during pregnancy were about 50% more likely of being admitted to a neonatal intensive care unit (NICU) than infants whose mothers never took these medications and about 20% more likely to require care in a NICU than infants whose mothers used these medications before or after but not during pregnancy.

Infants exposed to ADHD medications in utero were also more likely to experience central nervous system–related disorders such as seizures (odds ratio=1.9) and were more often born preterm (odds ratio=1.3) compared with infants who were not exposed to these medications. 

“These findings warrant attention but are hardly reasons to abstain from ADHD medication during pregnancy if treatment is crucial for the woman,” Nörby and colleagues wrote. “Because women who used these drugs during pregnancy in many ways differed from the average pregnant population, it is uncertain to what extent these associations can be explained by the ADHD medication itself.” 

Nörby and colleagues analyzed data from Swedish birth and medical registries, including nearly one million single births recorded between July 1, 2006, and December 31, 2014. They identified 1,591 infants (0.2%) who were exposed to ADHD medication during pregnancy (1,464 were exposed to stimulants and 165 were exposed to atomoxetine).

“Despite the authors’ effort to control possible confounding by using a comparison group who carried a diagnosis of ADHD, it is an imperfect control condition,” Kimberly Yonkers, M.D., a professor of psychiatry, epidemiology, and obstetrics, gynecology, and reproductive sciences at Yale University, told Psychiatric News. “Women who used ADHD medication were clearly different in many ways from the other two groups.” 

Yonkers added that the authors did not have information related to the use of illicit substances and alcohol in these women, which could be a contributing factor. She noted that the study found women taking ADHD medications reported much higher levels of nicotine use than those who did not, so it is possible that other substance use by this group was higher as well.

To read more about mental health and pregnancy, see the Psychiatric News PsychoPharm article “Yes or No: Prescribing Antidepressants to Pregnant Patients” by Jennifer L. Payne, M.D., and the American Journal of Psychiatry article “ADHD and Pregnancy” by Marlene P. Freeman, M.D.

(Image: iStock/Halfpoint)

Thursday, November 9, 2017

Antipsychotics May Increase Risk of Aspiration Pneumonia in Older Adults

Antipsychotics are commonly used in hospitals for non-psychiatric purposes, particularly to manage delirium in older hospitalized patients. A study published in the Journal of the American Geriatrics Society found that patients who received antipsychotics for a non-psychiatric purpose had about 40%-50% increased risk of aspiration pneumonia—an infection that occurs following the ingestion of solids or liquids into the lungs—than hospital patients without antipsychotic exposure.

“This association was robust through multiple analytical approaches and persisted when focusing on individuals with discharge diagnoses of delirium and dementia,” wrote lead author Shoshana Herzig, M.D., M.P.H., of Harvard Medical School and colleagues. The researchers also noted there was no association between antipsychotics and nonaspiration pneumonia, which supports the idea of a causal link between antipsychotic exposure and aspiration pneumonia.

Herzig and colleagues analyzed data on patients admitted to a large academic medical center in Boston from January 2007 through July 2013, excluding psychiatric hospitalizations (to focus on off-label antipsychotic use), transfers from other hospitals, or hospitalizations shorter than 48 hours.

Of the 146,552 hospitalizations included in the analysis, antipsychotics were used in 10,377 cases, or about 7%. Aspiration pneumonia occurred in 557 (0.4%) hospitalizations. The incidence of aspiration pneumonia was 1.2% in patients with antipsychotic exposure and 0.3% in unexposed individuals. After adjusting for factors such as patient age, length of hospital stay, and exposure to other medications, the authors found that antipsychotic exposure resulted in a 1.4-1.5 increased odds of aspiration pneumonia; the risks were the same for typical and atypical antipsychotics.

Herzig and colleagues also found that age did not impact the relative risk of aspiration pneumonia, but they pointed out that overall use of antipsychotics steadily increased with age. Exposure rates were 5.2% for patients 65 and under, 7.3% for patients 65-74, and 12.5% for patients 75 and older. As such, the absolute risks of aspiration pneumonia were higher in patients 75 and older.

“[O]ur findings suggest that targeting older adults for interventions aimed at improving antipsychotic prescribing practices will lead to the greatest absolute reduction in the occurrence of this costly and morbid complication,” the authors wrote.

To read more on this topic, see the Psychiatric News article “Mortality Risk High for Dementia Patients Taking Antipsychotics.


Wednesday, November 8, 2017

Guided Online CBT Program May Enhance Collaborative Care for Depression, Anxiety

Incorporating a computerized cognitive-behavioral therapy (CCBT) into a collaborative care program may lead to symptom improvements in patients with depression and anxiety beyond those reported by patients receiving usual care from a primary care physician (PCP), according to a study published today in JAMA Psychiatry

“Our report confirms the effectiveness of guided CCBT, highlights the critical importance of patient engagement with online interventions, and provides high-quality evidence about the limits and potential benefits of these emerging technologies,” wrote Bruce L. Rollman, M.D., M.P.H., of the University of Pittsburgh School of Medicine and colleagues.

The researchers recruited patients aged 18 to 75 years who were recently diagnosed with anxiety, generalized anxiety, panic, or depression from 26 primary care offices in Pittsburgh. Study participants were randomly assigned to one of three interventions for six months: (1) care manager–guided CCBT alone, (2) care manager–guided access to both CCBT and a moderated, password-protected Internet support group (CCBT+ISG), or (3) usual care under their PCP. 

Participants assigned to the CCBT program received an email and phone call from a care manager introducing the eight-session Beating the Blues CCBT program, which included text, audiovisual clips, and “homework” assignments on CBT techniques. Patients in the CCBT+ISG group were also encouraged to participate in moderated discussion boards or check out other resources on the Internet support group page. 

Care managers logged into the CCBT program’s portal to monitor patients’ progress, sent personalized feedback and encouragement via email, and called patients who either had not improved or failed to log in regularly. PCPs were regularly updated about their patients’ progress through electronic medical records. Participants in the usual care group were informed of their anxiety and mood symptoms, and referring PCP, but were not given treatment advice unless suicidality or significant worsening of symptoms was captured during assessments at three, six, and 12 months. 

Over the six-month period, 504 of 603 patients (83.6%) with CCBT access started the program and completed an average of 5.4 sessions. Overall, 228 of 302 patients (75.5%) in the CCBT+ISG arm logged into the Internet support group at least once; of these patients, 141 (61.8%) made at least one online comment or post. 

Patients receiving CCBT+ISG or CCBT alone reported significant improvements in mental health–related quality of life and mood and anxiety symptoms compared with patients receiving usual care at six months—improvements that were still evident when patients were reassessed six months after the intervention ended. The researchers also found that the more CCBT sessions the patients completed, the greater the improvement in their symptoms.    

“[A]lthough our ISG [Internet support group] did not produce any measurable benefit over CCBT alone, providing online CCBT to patients with depression and anxiety receiving primary care via a centralized collaborative care program is an effective strategy for delivering mental health care at scale,” the authors concluded.

For related information, see the Psychiatric News article “Early Follow-Up Is Key to Patient Success in Collaborative Care” and the American Journal of Psychiatry article Improving the Efficiency of Psychotherapy for Depression:Computer-Assisted Versus Standard CBT.”

(Image: iStock/izusek)

Tuesday, November 7, 2017

APA, Responding to Trump on Shooting, Seeks Action on Mental Health

In response to remarks by President Donald Trump this week that the deadly shooting in a Texas church Sunday morning was “a mental health problem,” APA called on the administration and Congress to strengthen and improve access to quality mental health care.

“We are deeply saddened by the senseless violence in a house of worship this weekend,” said APA CEO and Medical Director Saul Levin, M.D., M.P.A., in a statement following the shooting in which 26 people were killed and more than 20 injured when a gunman opened fire at a Baptist church. “We extend our deepest sympathies to the victims, the families, and the community of this tragedy.”

He added that though the president and lawmakers have made comments associating acts of violence with mental illness, research has consistently shown that people with mental illness are not more likely to be perpetrators of violence, but more likely to be victims. In his statement, Levin requested that lawmakers not perpetuate stigma by making premature statements.

“If lawmakers believe it is a mental health issue, why are they not seeking to ensure that more resources are being put into treating those with mental health issues?” Levin asked.

Levin said that for policymakers who are sincere about addressing mental health, a first step is to protect “essential health benefits” in the Affordable Care Act (ACA), which include treatment for mental illness and substance use; those essential health benefits have been targeted in repeated Republican attempts to repeal or replace the ACA. 

“More designated funding should be appropriated to the National Institute of Mental Health, National Institute on Drug Abuse, and National Institute on Alcohol Abuse and Alcoholism at the National Institutes of Health to focus on new research to help increase new knowledge on how to prevent, treat, and cure mental illness and substance use disorders,” Levin added. “In addition, APA calls on the administration, the Congress, and state legislators to take needed steps to ensure that access to mental health programs remain intact so people with mental illness and substance use disorders are getting the care they need. The American Psychiatric Association stands ready to help you achieve that goal.”

Monday, November 6, 2017

High Rates of Polypharmacy Found Among Adults With Intellectual Disability Seeking Psychiatric Care

By the time adults with intellectual disability sought specialized psychiatric outpatient services in a Canadian clinic, 70% had already been prescribed one psychotropic medication, and 22% had received three or more psychotropic medications, according to a study in Psychiatric Services in Advance. The findings underscore the importance of educating non-specialist providers about prescribing guidelines for this patient population.

“Understanding the demographic, organizational, and clinical characteristics that place individuals at greater risk of polypharmacy may help in the design of future intervention efforts,” wrote lead author Yona Lunsky, Ph.D., a professor in the Department of Psychiatry at the University of Toronto, and colleagues.

The researchers identified predictors of psychotropic polypharmacy using a retrospective chart audit for patients referred to a specialized psychiatric outpatient clinic for people with intellectual disabilities in Canada between 2005 and 2013. Predictors that psychotropic polypharmacy was likely to occur among these patients included (1) living in a supervised residential setting; (2) having a diagnosis of anxiety, mood, or psychotic disorder; (3) having a diagnosis of psychiatric complexity (two or more diagnostic categories); and (4) being a woman. 

In this study and a prior study, polypharmacy rates were not associated with the severity of intellectual disability or autism spectrum disorder.

The study sample consisted of 517 outpatients (199 females; 318 males) aged 15 to 73 in an urban, tertiary-level mental health care facility in Ontario, Canada. Before receiving specialist care, these individuals with intellectual disability received their medications from either family physicians or general psychiatrists. 

Of the 70% of the study patients prescribed at least one psychotropic medication, 146 (40%) had no psychiatric diagnosis on their intake form. One hundred and twelve (22%) referred to the service received three or more psychotropic medications concurrently, 30 of them without having any psychiatric diagnosis. The most commonly prescribed medication class was antipsychotics (n=275, 53%), followed by antidepressants (n=151, 29%). The most common interclass polypharmacy combination was antipsychotics, mood stabilizers, and antidepressants (n=52). 

“Although there are circumstances in which psychotropic polypharmacy may be warranted, guidelines suggest that intraclass polypharmacy be avoided, that medications for behavior management be offered in combination with psychological or other interventions, and that there be regular monitoring of medication use, with the goal of reducing multiple medications when possible,” the authors wrote. “Both psychiatrists and family physicians can play a role in the judicious use of medications for this vulnerable population.”

(Image: iStock/smartstock)

Friday, November 3, 2017

U.S. Senators, MH Advocates Among Recipients of American Psychiatric Excellence (APEX) Awards

APA today recognized five leaders in politics, journalism, and advocacy for drawing attention to the needs of people with mental illness and substance use disorders during the second American Psychiatric Excellence (APEX) Awards presentation in Washington, D.C.

Honorees included Resident Commissioner Jenniffer González-Colón (R-Puerto Rico; pictured at left with APA Assembly Speaker Theresa Miskimen, M.D.); Kathryn Farinholt, executive director of NAMI Maryland; U.S. Sen. Brian Schatz (D-Hawaii); U.S. Sen. Debbie Stabenow (D-Mich.); and Eric Eyre, a reporter for the Charleston Gazette-Mail.

As resident commissioner, Jenniffer Gonzalez-Colon is the sole representative from Puerto Rico to Congress and helped secure $36.5 billion in disaster aid for the island in the wake of Hurricane Maria. “This money will be essential as communities clean up, rebuild, and work to recover both physically and mentally,” said Miskimen before presenting the award to González-Colón.

Kathryn Farinholt helped develop the NAMI Family Support Group program, the “NAMI In Our Own Voice: Living With Mental Illness” training for NAMI representatives, and other signature NAMI programs.

Sen. Brian Schatz co-sponsored the Expanding Capacity for Health Outcomes (ECHO) Act, which was enacted in 2016 to help expand telemedicine and telepsychiatry. He is also a lead sponsor of the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act, which is also designed to expand technology-supported access to health care. The CONNECT for Health Act is endorsed by APA. Accepting for Schatz, who could not attend, was his health policy advisor, Amy Grace, M.D., a pediatrician.

Sen. Debbie Stabenow has used her position on the Senate Finance Committee to protect “essential health benefits,” including mental health benefits, in recent efforts to reform or overturn the Affordable Care Act (ACA). She helped make mental health parity a priority in the ACA and has helped pass legislation to expand the health care workforce. Stabenow was unable to attend but her award will be presented to her at a later date.

Eric Eyre is a statehouse reporter for the Charleston Gazette-Mail whose reporting has examined the opioid crisis in West Virginia and the role of pharmaceutical companies in distributing opioids in the state. He received the 2017 Pulitzer Prize for his reporting.

“The APEX Awards were created to honor the people who work every day to make our communities a better safer place for people living with mental illness and substance use disorders,” said APA President Anita Everett, M.D., at the ceremony. “They have helped move the needle on so many different fronts—by working with people with mental illness and their families; fighting for resources so communities can recover from a major disaster; promoting new ways to deliver mental health care and substance use disorder treatments; and by speaking up about the deadly effects of opioids on communities throughout our country.”

APA CEO and Medical Director Saul Levin, M.D., M.P.A., added, “Each of these awardees in their own way has contributed to our common goal of making the United States a better, safer place for those with mental illness and substance use disorders.

(Image: David Hathcox)

Thursday, November 2, 2017

APA Pledges Support of Efforts to Address Opioid Crisis

Following the release of the final report by the President’s Commission on Combating Drug Abuse and the Opioid Crisis on Wednesday, APA pledged its support to work with the Trump administration, Congress, and states to address the nation’s opioid crisis.

“The APA welcomes the final report because it helps bring much-needed attention to this crisis,” said APA CEO and Medical Director Saul Levin, M.D., M.P.A. "Our organization trains thousands of clinicians each year in the diagnosis and treatment of those with opioid use disorders. Additionally, we are an active partner in the Providers’ Clinical Support System for Medication Assisted Treatment coalition funded by SAMHSA. This national initiative provides training and mentoring in response to the prescription opioid misuse epidemic and increases the availability of pharmacotherapies to address opioid use disorder.”

The 138-page report includes more than 50 recommendations, broken down into the following categories:
  • Federal funding and programs
  • Opioid addiction prevention
  • Opioid addiction treatment, overdose reversal, and recovery
  • Research and development
In an initial response to the report, APA was pleased to see that it includes some of its recommendations such as enforcement of the Mental Health Parity and Addiction Equity Act, the development of a national media campaign to address the stigma of substance use, improved data surveillance systems, and improved access to drug courts and medication-assisted treatment in the criminal justice system. While the report aims to provide a comprehensive strategy for addressing the opioid crisis, however, APA noted that it does not include a funding request to implement many of the recommendations.

In a letter addressed to President Donald Trump introducing the report, New Jersey Gov. Chris Christie, chairman of the President’s Commission on Combating Drug Abuse and the Opioid Crisis, wrote, “It is time we all say what we know is true: addiction is a disease. However, we do not treat addiction in this country like we treat other diseases. Neither government nor the private sector has committed the support necessary for research, prevention, and treatment like we do for other diseases.”

He continued, “As you will see in the Commission’s recommendations, the Federal Government has a number of avenues through which it can ensure that individuals with addiction disorders get the help they need, including changing CMS reimbursement policies, enforcing parity laws against non-compliant insurers, promoting access to rural communities through such tools as telemedicine, and incenting a larger treatment workforce to address the broad scope of the crisis.”

Levin added, “We are still reviewing the report’s contents for a full evaluation, but we stand ready to work with the administration, Congress, and the states to help provide education, funding, training, and support to address the opioid crisis.”

(Image: iStock/bboserup)

Wednesday, November 1, 2017

Long-Term Use of Hypnotics Up Significantly From 1999 to 2014, Study Finds

Long-term use of benzodiazepine (BZD) and non-benzodiazepine hypnotics (NBH) appears to have grown significantly during a 15-year period between 1999 and 2014, independent of demographic shifts, according to a report today in Psychiatric Services in Advance.

Because clinical guidelines suggest that both types of medications should be used on a short-term basis, the findings highlight “the pressing need for better delineation of appropriate medium- and long-term use of these medications,” wrote lead author Christopher Kaufmann, Ph.D., M.H.S., of the University of California, San Diego, and colleagues.

The researchers analyzed data from eight waves of the National Health and Nutrition Examination Survey (NHANES) between 1999 and 2014. NHANES interviewers recorded medications used during the preceding month based on prescription bottles provided by participants, and participants reported duration of use for each medication. BZDs included alprazolam, chlordiazepoxide, clonazepam, clorazepate, diazepam, estazolam, flurazepam, lorazepam, oxazepam, temazepam, and triazolam. NBHs included zolpidem, zaleplon, and eszopiclone.

Kaufmann and colleagues found that use of both types of drugs increased significantly over the study period, from 2.0% of respondents in 1999-2000 to 4.2% in 2013-2014 for BZDs and from 0.4% in 1999-2000 to 1.6% in 2013-2014 for NBHs. Trends were driven by increases in use of more than six months.

In 2013-2014, virtually all of the 96 listed NBHs (97.9%) were used for sleep problems, and of these 94 NBHs, 85.1% were used on a medium- or long-term basis. Among the 290 BZDs listed, 60.3% were used for anxiety problems, 29.3% for sleep problems, and 11.4% for mood problems. About 83% of BZDs used for anxiety problems were for medium- or long-term use, as were most BZDs used for sleep problems (84.7%) and mood problems (81.8%).

“Monitoring of long-term BZD and NBH use, particularly in vulnerable patients (for example, older adults), may be important for understanding the reasons for changing patterns of use of these medications and prevention of potential adverse health outcomes associated with their use,” the authors wrote. “Additionally, promoting the availability of behavioral sleep treatments may help reduce the need for pharmacological sleep interventions, because sleep problems remain a major reason for their long-term use.”

For related information, see the Psychiatric News article “Tips for Reducing Suicide Risk When Prescribing Hypnotics.”

(Image: vadimguzhva/

Tuesday, October 31, 2017

Alleviating Conflict Between Work, Home Life May Improve Physician Mental Health

The medical internship year can be a challenging time for many physician trainees. A study published yesterday in JAMA Internal Medicine found that female medical interns are more likely than male medical interns to experience symptoms of depression. The study also found that the sex disparity in depression during the internship year may be driven in part by increasing conflict between work and personal obligations (work-family conflict). 

“Systemic modifications to alleviate conflict between work and family life may improve physician mental health and reduce the disproportionate depression disease burden for female physicians,” wrote psychiatrist Constance Guille, M.D., of the Medical University of South Carolina and colleagues. “Given that depression among physicians is associated with poor patient care and career attrition, efforts to alleviate depression among physicians has the potential to reduce the negative consequences associated with this disease.”

Guille and colleagues invited medical students matching to residency programs across all specialties throughout the United States during the 2015-2016 academic year to complete online assessments two months prior to the start of the internship year and again at six months into the internship year. As part of these assessments, the participants were asked to report depressive symptoms using the Patient Health Questionnaire (PHQ-9) and the degree to which work responsibilities interfered with family life (“family” was defined from participants’ perspective) using the Work and Family Conflict Scale.

Of the 3,121 students entering internships who completed the initial survey, 2,108 completed the six-month survey. The authors found that while men and women experienced a marked increase in depressive symptoms and work-family conflict over the first six months of their internship year, the increase in depressive symptoms among women was higher than the increase among men (mean increase in PHQ-9: 3.20 versus 2.5). When work-family conflict was accounted for, the sex disparity in the increase in depressive symptoms decreased by 36%.

The findings suggest that “work-family conflict [is] an important potentially modifiable factor associated with elevated depressive symptoms in training physicians,” Guille and colleagues wrote.

“Pilot programs designed to ease work-family conflicts among physicians through providing free home-delivered meals, childcare, and housecleaning are in their infancy,” the authors wrote. “Our findings suggest that these programs should be expanded in scope and number and that they should be rigorously tested to see if they not only reduce work-family conflict but also depression and its consequences, such as physician suicide, poor quality of patient care, medical errors, and career attrition.” 

For more about what APA is doing to address physician burnout and wellness, see the Psychiatric News article “Working Toward Wellness: Exploring Burnout and Resiliency in Physicians” by APA President Anita Everett, M.D. Addressing physician burnout and improving wellness is one of Dr. Everett's presidential initiatives.

For additional related information, see the Psychiatric News articles “How I Became Active in Fight For Trainee Wellness” by Matthew L. Goldman, M.D., M.S., and “Suicides of Young Physicians Raise Alarm About Burnout Among Trainees” by Carol Bernstein, M.D.

(Image: iStock/PeopleImages)

Monday, October 30, 2017

Niacin Skin Test May Identify Some Patients With Schizophrenia

Researchers may be one step closer to determining how a topical niacin test—which rapidly causes the skin to flush—might be used to objectively identify some patients with schizophrenia, according to a study published in Schizophrenia Bulletin

Previous studies have observed a link between a diminished niacin response and schizophrenia, but due to small sample sizes it has been difficult to pinpoint a quantitative cutoff that can accurately distinguish patients. In the current study, Chunling Wan, Ph.D., of Shanghai Jiao Tong University in China and colleagues calculated the degree of inflammatory response to topical niacin that can objectively identify some patients with schizophrenia. 

The study included 163 subjects with schizophrenia, 63 subjects with a mood disorder (depression, mania, or bipolar disorder), and 63 healthy controls from the Chinese Han population. All the participants received a comprehensive skin test that involved applications of niacin at four concentrations (0.1, 0.01, 0.001, and 0.0001 M) on the forearm. Each participant was given a score based on the skin flush response at 5, 10, 15, and 20 minutes after application.

The authors observed that overall, the schizophrenia group showed both delayed and decreased skin flush reactions after niacin stimulation, while the group with mood disorders exhibited delayed but not decreased flushing relative to controls.

After calculating various parameters, the study authors found that patients who had a total score of less than 20 and a score of less than 2.5 on their 0.1 M application after 15 minutes could be identified as having schizophrenia with about 88% accuracy in males and 84% accuracy in females. In total, 23% of male patients with schizophrenia and 42% of female patients fell below this cutoff.

Upon being ingested or applied to the skin, the vitamin niacin triggers a physiological response that dilates blood vessels and causes skin reddening in the first 30 minutes; a key part of this response is the release of the fatty acid arachidonic acid (AA) from cell membranes. 

“This subgroup of SZ [schizophrenia] patients may share common abnormalities in the membrane phospholipid-AA-prostaglandin pathway, in fatty acid metabolism or even in the endogenous niacin concentration,” Wan and colleagues wrote. “Such abnormalities could have etiological implications for SZ, providing new angles to explore the disease. More importantly, it can also facilitate the design of efficient drugs for targeted treatment of these niacin-blunted SZ patients in the future.”
(Image: iStock/bluecinema)

APA to Honor MH Advocates Who Have Made a Difference

Members of the APA Assembly are invited to attend a luncheon on Friday, November 3, for the presentation of the 2017 American Psychiatric Excellence (APEX) Awards. The awards recognize individuals who have demonstrated the highest levels of advocacy on behalf of people with mental illness. The luncheon will be held from noon to 1 p.m. in the Ambassador Ballroom of the Omni Shoreham in Washington, D.C.—immediately before the start of the Assembly’s fall meeting. RSVP now.  

Friday, October 27, 2017

E-Cigarette Use Can Lead to Smoking Tobacco Cigarettes, Study Suggests

E-cigarette vaping can lead adolescents eventually to smoking combustible cigarettes, according to a study published this week in JAMA Pediatrics.

“Adolescents who use e-cigarettes with higher levels of nicotine may be at greater risk for developing a tolerance to and dependence on nicotine that could contribute to the persistence and progression of vaping as well as use of combustible tobacco products,” wrote corresponding author Adam M. Leventhal, Ph.D., of the University of Southern California Keck School of Medicine and colleagues. 

In this cohort of 181 adolescent e-cigarette users (96 boys and 85 girls), the use of electronic cigarettes with higher nicotine concentrations at baseline was associated with greater levels of combustible cigarette and electronic cigarette use at the six-month follow-up.

Tenth graders from the Los Angeles metro area were asked about the number of days they smoked cigarettes and used e-cigarettes within the past 30 days, the frequency of smoking/vaping on these days, and the level of nicotine used in e-cigarettes (none [0 mg/mL], low [1-5 mg/mL], medium [6-17 mg/mL], high [≥18 mg/mL]). At a six-month follow-up, the students were again asked about the number of days that they had smoked cigarettes and used e-cigarettes within the past 30 days, and the frequency of smoking/vaping on these days.

Each successive increase in nicotine concentration (none to low, low to medium, and medium to high) vaped was associated with a 2.26 increase in the odds of frequent (versus no) smoking and a 1.65 increase in the odds of frequent (versus no) vaping at follow-up after adjustment for baseline frequency of smoking and vaping and other relevant covariates.

“To our knowledge this is the first prospective study to evaluate the association of varying e-cigarette nicotine concentrations with future smoking and vaping behavior,” the researchers noted.

For related information, see the Psychiatric News article “Could FDA’s Proposed Plan Help Smokers With Mental Disorders Quit For Good?

(Image: iStock/JANIFEST)

Thursday, October 26, 2017

Diagnosing Late-Onset ADHD May Require Ruling Out Substance Use, Other Disorders

Although some patients who screen positive for attention-deficit/hyperactivity disorder (ADHD) in adolescence or adulthood may represent valid late-onset cases, a study in AJP in Advance suggests there may be other explanations for the emergence of ADHD symptoms later in life.

After using a multistep assessment that took into consideration psychiatric symptoms, impairment, and substance use patterns from childhood to adulthood, Margaret Sibley, Ph.D., of Florida International University in Miami and colleagues concluded approximately 95% of the patients who initially screened positive on symptom checklists should not be diagnosed with late-onset ADHD. 

“Among individuals with impairing late-onset ADHD symptoms, the most common reason for diagnostic exclusion was symptoms or impairment occurring exclusively in the context of heavy substance use,” Sibley and colleagues wrote. “Prior to diagnosing or treating ADHD in late-onset cases, clinicians should carefully assess and treat substance use and comorbid mental health disorders as a potential source of symptoms.”

Sibley and colleagues analyzed data on 239 individuals who were not diagnosed with ADHD as children but participated in the Multimodal Treatment Study of ADHD as part of the trial’s comparison group (a sample drawn from the same local school, sex, and age/grade pool as the ADHD sample in the study). Participants in the comparison group received regular assessments over a 14-year period, including parent, teacher, and self-reports of ADHD symptoms, ADHD-related impairment, substance use, and other mental disorders.

Of the 239 comparison group participants, “53% of adolescents and 83% of adults who met all symptom, impairment, and late-onset criteria for ADHD were excluded because symptoms or impairment were better explained by heavy substance use or another mental disorder,” the authors reported.

They added, “The majority of adolescent-onset cases possessed transient symptoms. Thus, it may be appropriate to give provisional first-time ADHD diagnoses in adolescence and to monitor symptoms over time, as remission may occur within a few years. Further research is needed to understand how cognitive immaturity or adolescent neurocognitive changes might mimic or facilitate emerging ADHD symptoms.”

For related information, see the Psychiatric News article “Study Suggests ADHD in Adults May Be Distinct Disorder.”

(Image: Alexander Raths/Shutterstock)

Wednesday, October 25, 2017

Everett, Others Discuss Importance of MH Block Grants at Hill Briefing

Anita Everett, M.D., medical director of the Substance Abuse and Mental Health Services Administration (SAMHSA), participated in a Capitol Hill briefing yesterday on the importance of the agency’s Community Mental Health Services Block Grant (MHBG) program.

The MHBG program provides funds and technical assistance to all 50 states, the District of Columbia, Puerto Rico, the U.S. Virgin Islands, and U.S. Pacific to support comprehensive, community mental health services. The program funds are divided among the states and territories based on the estimated at-risk population.

“These block grants are a small but vital part of a state’s health care funding,” said Everett, who is also president of APA. “They provide flexibility for states to implement new, evidence-based strategies that are not covered by insurance.” The grantees have leeway in how they spend the money, although a provision added by Congress in 2015 mandates that 10% of each grant be set aside specifically for early psychosis intervention programs. These programs identify as early as possible people who have experienced their first episode of psychosis and use a comprehensive, team-based approach to prevent or delay the onset of serious mental illness, such as schizophrenia or bipolar disorder, and reduce relapse episodes.

For the most recent fiscal year, the SAMHSA budget included $533 million for MHBG grants, and thus $53 million set aside for early psychosis programs. Everett and the other speakers at the Capitol Hill briefing, which was hosted by the National Alliance on Mental Illness (NAMI), discussed multiple studies demonstrating how individuals who have experienced a first episode of psychosis benefit from early psychosis programs. For example, Everett highlighted the Alexandria, Virginia-based program TRAILS (Transitioning Adults Into Living Successfully), which has successfully placed 74% of the program’s clients in jobs or school.

Everett said there is a growing momentum for implementing these early psychosis programs, and she hopes that resources will continue to be available to expand these services.

To read more about early psychosis interventions, see the Psychiatric News articles “Digital Advertising Is Effective Tool for Engaging People on Early Psychosis” and “Psychosocial Treatments Found Effective for Early Psychosis.”

(Sylvia Johnson)

Tuesday, October 24, 2017

Extended-Release Naltrexone as Effective, Safe as Buprenorphine-Naloxone, Study Finds

Treatment with extended-release naltrexone appears to be as safe and effective as daily oral buprenorphine-naloxone in maintaining short-term abstinence from heroin and other illicit substances in newly detoxified individuals, according to a study in JAMA Psychiatry. The findings were based on a 12-week, multicenter, outpatient, open-label trial conducted at five addiction clinics in Norway. 

After detoxification, 159 opioid-dependent adults (according to DSM-4) were randomly assigned to either daily oral flexible dose buprenorphine-naloxone (4 mg/d to 24 mg/d) or extended-release naltrexone hydrochloride (380 mg, administered intramuscularly every fourth week) for 12 weeks. At the start of the trial and again at 4, 8, and 12 weeks, patients underwent a structured interview using the European version of the Addiction Severity Index covering drug use, physical and mental health, work, education, and criminal activity. 

Treatment with extended-release naltrexone was found to be as effective as buprenorphine-naloxone at maintaining retention in treatment (mean number of days until dropout from study medication: 69.3 days and 63.7 days of 84 days, respectively). Additionally, there were no significant differences between the treatment groups in the proportion of opioid-negative urine drug tests, or pattern of use of amphetamine, cocaine, alcohol, cannabis, or injecting drugs. 

Participants receiving extended-release naltrexone reported significantly less heroin craving and thoughts about heroin than did buprenorphine-naloxone participants, as well as greater treatment satisfaction. Individuals in the extended-release naltrexone group reported more adverse events than those in the buprenorphine-naloxone group (49 [69.0%] vs 25 [34.7%]). Some of these events were related to induced or experienced withdrawal symptoms, such as nausea, chills, shivering, diarrhea, and sneezing, the authors reported.

“Maintaining short-term opioid abstinence with extended-release naltrexone should be considered an equal treatment alternative to buprenorphine-naloxone as medication-assisted treatment for opioid-dependent individuals,” Lars Tanum, M.D., D.M.Sc., of the University of Oslo in Norway and colleagues wrote.

For related information, see the Psychiatric News article “Low-Dose Naltrexone May Mitigate Severity of Opioid Withdrawal During Detox" and the Psychiatric Services article “Fentanyl and the Evolving Opioid Epidemic: What Strategies Should Policy Makers Consider?.”

(Image: iStock/Ca-ssis)

Monday, October 23, 2017

Technical, Clinical Advances Make ECT Safe, More Effective for More Patients

Electroconvulsive therapy (ECT) should be regarded as a valuable treatment for severe major depression based on severity of illness, “not just because all other treatments have failed,” said Charles Kellner, M.D., the chief of electroconvulsive therapy at New York Community Hospital, Brooklyn, during a workshop Saturday at APA’s fall meeting IPS: The Mental Health Services Conference in New Orleans.

Technical and clinical advances have vastly improved the effectiveness and tolerability of ECT for patients with severe depression, and research is now beginning to elucidate how ECT works, he said. Kellner was joined at the session by Robert Greenberg, M.D., chief of geriatric psychiatry at New York University Langone Health, Brooklyn Campus; Adriana Hermida, M.D., of Emory University School of Medicine; and Robert Cotes, M.D., associate director of psychiatry residency education at Emory.

Advances in ECT include technical improvements such as the development of ultra-brief pulse wave ECT. This type of ECT has been shown to substantially diminish the risk of cognitive effects, the biggest fear among patients and family members regarding the treatment. “Modern ECT causes far less retrograde amnesia [than in the past],” Kellner said. “For seriously depressed patients, [concern about this side effect] should not be a deal-breaker.”

Despite improvements in ECT technology and evidence of the effectiveness of the therapy, Kellner told session attendees that the “biggest obstacle to the use of ECT are reservations about the treatment that cannot be explained [rationally].”

Kellner noted that allowing family members to be present for administration of ECT is an important way to diminish stigma about the treatment. “For many family members it is beneficial for them to stay in the treatment suite for the entire procedure,” Kellner said. “Family members are relieved to see that ECT is banal, quick, smooth, and safe.”

Kellner added that there have been new diagnostic indications for ECT, such as for treatment of self-injurious behavior related to autism. He added that the Centers for Medicare and Medicaid Services (CMS) is considering approval of a code for use of ECT in ambulatory surgical centers. “If that becomes available, it will be a major breakthrough for ECT access,” Kellner said.

Look for further coverage of IPS: The Mental Health Services conference in Psychiatric News.

Friday, October 20, 2017

IPS Town Hall Focuses on NIMH Goals, Call for Ideas

The National Institute of Mental Health’s (NIMH) Division of Services and Intervention Research (DSIR) is “open for business,” said division director Robert Heinssen, Ph.D., at a special session yesterday at APA’s fall conference, IPS: The Mental Health Services Conference, in New Orleans.

Heinssen noted that a combination of Congressional funding and a drive by new NIMH Director Joshua Gordon, M.D., to accelerate the institute’s public health impact has led to the availability of resources for developing innovative interventions that can reach more people with mental illness. "We are looking for good ideas," he said.

One area of particular interest, Heinssen said, are clinical studies on interventions that factor in end-user deployment issues—that is, intervention designs that already take into account the characteristics or limitations of the target service area. For example, a study could include behavioral therapy in a bilingual format to make an intervention useful in a strongly Latino community or require limited resources so that even a small community clinic could afford the intervention. Once validated in research, these strategies could be rapidly disseminated where needed.

NIMH is also interested in harnessing the power of existing digital technology that incorporates principles from social psychology, such as affirmation and positive reinforcement, to provide “24/7” support to people with mental illness. Such tools include smartphone apps that allow continuous patient communication and technologies like “asynchronous telepsychiatry” in which interviews of patients by trained staff are videotaped for review by psychiatrists at a later time.

These comments were part of a townhall discussion by three leaders from the National Institutes of Health who described the current themes or strategies of their respective institutes. In addition to Heinsenn, the presenters were Wilson Compton, M.D., M.P.E., deputy director of the National Institute on Drug Abuse, and Aaron White, Ph.D., a senior scientific advisor to the director at the National Institute on Alcohol Abuse and Alcoholism.

(Image: Nick Zagorski)

Thursday, October 19, 2017

Pfister Award Winner Describes Brief Psychotherapy Modules for Hope in the Midst of Demoralization

Hope is a natural antidote to despair and demoralization experienced by psychiatric patients that can be encouraged and supported through brief “hope” interventions that can be employed in crisis situations, according to James L. Griffith, M.D. Griffith delivered APA’s 2017 Oskar Pfister Award lecture today at IPS: The Mental Health Services Conference in New Orleans.

Griffith, the chair of psychiatry at George Washington University (GWU) School of Medicine, described his work developing brief intervention modules that help patients practice hope in demoralizing life situations and that can be taught to trainees and other mental health clinicians. His work on the subject was published in an article in Academic Psychiatry (July 2017).

“Despair from demoralization is a constant threat to patients with chronic mental illnesses, refugees fleeing persecution, elderly who are socially isolated, the medically disabled, and other marginalized or displaced people,” Griffith said.

Griffith said that he and his colleagues have identified 14 discrete psychotherapeutic practices, or interventions, in the psychotherapy literature that foster hope in patients. These practices correspond to one of four types of coping (problem solving and goal seeking, activating a core identity, emotion regulation, and relational coping) that clinicians can use depending on the strengths of the specific patient. Moreover, they can be employed in a crisis situation without formal psychotherapeutic training.

He described several clinical vignettes in which the “hope” modules were employed to meet and challenge the demoralizing life situations faced by individual patients. For instance, he described a suicidal patient in despair because her house was being foreclosed, and her dog—a companion of many years—had recently died.

A second-year resident at GWU, with no formal training in psychotherapy, asked the patient, “In the past when you faced adversity, what did you do?” The patient recalled when her father, on his deathbed, told her she “was a strong fighter” and the “glue that held the family together.”

These were affirmations that drew on this patient’s strength, activating her core identity. The resident advised the patient to find a picture of her father and look to it whenever she felt despair. The resident also advised the patient to reach out to her children. These actions began a process of rebuilding the patient’s sense of self-efficacy and control over her own fate.

Griffith said that to design psychotherapeutic interventions that help people practice hope, they must be usable in the real-life conditions in which patients find themselves. 

“They must be usable under the often-chaotic conditions of refugee life, homelessness, poverty, or medical or psychiatric illness where a clinician may have only one or two conversations in settings ill-suited for psychotherapy,” he said.

Look for further coverage of IPS: The Mental Health Services conference in upcoming editions of Psychiatric News.

(Image: Ellen M. Dallager)

Wednesday, October 18, 2017

App Improves Mental Health Service Delivery to Pregnant Women With Symptoms of Depression

A smartphone application that tracks mood changes and alerts providers if symptoms worsen appears to improve service delivery and patient engagement among pregnant women with perinatal depression symptoms, according to a report in Psychiatric Services in Advance.  

The findings suggest such an app “is a feasible option to improve mental health service delivery via monitoring at-risk patients between visits,” wrote Liisa Hantsoo, Ph.D., and colleagues at the University of Pennsylvania Perleman School of Medicine. “[T]his app also facilitated patient-provider contact when needed rather than relying on the patient to decide to send an electronic message to her provider through a [patient portal].”

Hantsoo and colleagues recruited pregnant women (aged 18 and older; 32 weeks gestation or less) with depressive symptoms (≥5 on the Patient Health Questionnaire-9 [PHQ-9]) during a routine prenatal appointment at a clinic within an academic medical center serving a predominantly low-income and racial-ethnic minority population. To be included in this trial, the women had to own a smartphone with an iOS or Android operating system and speak English.

Seventy-two participants were randomly assigned to either a mobile app allowing access to a standard patient portal used for all patients at the health center that enabled email-like communication with providers (n=24) or to the patient portal with the addition of a mood tracking and alert (MTA) app (n=48). The MTA app alerted providers when participant mood symptoms worsened, prompting the provider to contact the participant. 

The researchers assisted the study participants with downloading the app(s), provided written materials explaining the apps, and administered a baseline interview, where care engagement and satisfaction were assessed. After eight weeks, care engagement and satisfaction were reassessed, and service delivery data on patient-provider contacts during the eight-week period were extracted from the electronic health record of each participant. Within the MTA group, depressive and anxiety symptoms were assessed after eight weeks.

Compared with the patient portal group, the MTA group had significantly more telephone encounters with providers that mentioned mental health. Within the MTA group, 17 women (41%) received a phone call from a provider that was triggered by an alert from the app. These women had a significantly higher rate of referral to a mental health provider compared with women who did not receive an MTA app–triggered contact. As gestational age increased, MTA users rated their ability to manage their own health significantly better than women in the control group.

The mean daily mood score was significantly positively correlated with the number of calls that a participant in the MTA group received in weeks 1 to 4. Participants who received an MTA-triggered call had consistently higher PHQ-9 and Generalized Anxiety Disorder (GAD-7) scores across the eight weeks compared with those who did not receive an MTA-triggered call. Among MTA users, PHQ-9, GAD-7, and self-reported daily mood scores significantly improved over eight weeks.

For related information, see the Psychiatric News PsychoPharm article, “FDA Clears First Prescription-Based ‘Digital Therapeutic’.”

(Image: shironosov/

Tuesday, October 17, 2017

Candidates Announced for APA's 2018 Election

The APA Nominating Committee, chaired by APA Immediate Past President Maria A. Oquendo, M.D., Ph.D., today announced the candidates for the Association's 2018 election.

Glenn A. Martin, M.D.
Bruce J. Schwartz, M.D.
Stephen M. Strakowski, M.D.

Brian Crowley, M.D.
Gregory W. Dalack, M.D.

Robert E. Feder, M.D.
Richard F. Summers, M.D.

Early Career Psychiatrists Trustee-at-Large
Héctor Colón-Rivera, M.D.
Mark A. Haygood, D.O., M.S.
Ayana Jordan, M.D., Ph.D.

Area 1 Trustee
John M. De Figueiredo, M.D.
Eric M. Plakun, M.D.

Area 4 Trustee
Ronald M. Burd, M.D.
Cheryl D. Wills, M.D.

Area 7 Trustee
Annette M. Matthews, M.D.
James A. Polo, M.D., M.B.A.
Joshua Sonkiss, M.D.

Resident-Fellow Member Trustee-Elect
Anne Clark-Raymond, M.D.
Rana Elmaghraby, M.D.
Helena Winston, M.D.

The deadline for candidates who wish to run by petition is November 15. All candidates and their supporters are encouraged to review APA's Election Guidelines. For more election information, please visit the Election section on APA's website or email

The slate of candidates who have been nominated is considered public but not official until it is approved by the APA Board of Trustees at its December meeting. APA members may cast their ballots from January 2 to January 31, 2018.

(Image: Sergey Ivanov)

Monday, October 16, 2017

Lurasidone Benefits Youth With Bipolar Depression Without Major Side Effects

Lurasidone appears to be well tolerated and effective at reducing depressive symptoms in children and adolescents with bipolar I depression, reports a study published Friday in Journal of the American Academy of Child and Adolescent Psychiatry

After six weeks, youth with bipolar depression assigned to daily lurasidone showed significant improvements in their Children’s Depression Rating Scale–Revised (CDRS-R) scores compared with those assigned to placebo. Youth taking lurasidone also demonstrated improvements in anxiety, quality of life, and global functioning.

“In addition to significantly higher responder rates in patients treated with lurasidone versus placebo, the clinical relevance of improvement in the lurasidone group is underscored by the observed change in mean [global functioning] score from <50 at baseline (‘moderate-to-severe impairment in functioning’) to >60 at study endpoint (‘generally functioning pretty well’),” wrote Melissa DelBello, M.D., of the University of Cincinnati College of Medicine and colleagues. “The consistency of improvement across primary, key secondary, and all other secondary efficacy measures further substantiates the overall effectiveness of lurasidone in this pediatric population with bipolar depression.”

This study included 347 pediatric patients aged 10 to 17 with bipolar I disorder and CDRS-R scores of at least 45. The participants were randomly assigned to either lurasidone (20-80 mg daily) or placebo. At the study endpoint, CDRS-R total scores dropped 21 points in the lurasidone group compared with 15.3 points in the placebo group. Overall response rates (≥50% reduction from baseline to week 6 in CDRS-R total score) were 59.5% and 36.5% for the lurasidone and placebo groups, respectively.

DelBello and colleagues noted the improvements seen in the current study were comparable to those seen in a clinical trial of olanzapine/fluoxetine combination (OFC) therapy, but lurasidone had a better tolerability profile. 

The dropout rates among patients due to adverse events were low and similar for both groups in the lurasidone study (1.7% compared with 14.1% in the aforementioned OFC study). The two most common adverse events among patients taking lurasidone were nausea and somnolence. There were no significant differences in weight gain between lurasidone and placebo groups.

For related information, see the FOCUS article “Management of Bipolar Disorder in Children and Adolescents,” by DelBello and colleagues.

(Image: iStock/gradyreese)


The content of Psychiatric News does not necessarily reflect the views of APA or the editors. Unless so stated, neither Psychiatric News nor APA guarantees, warrants, or endorses information or advertising in this newspaper. Clinical opinions are not peer reviewed and thus should be independently verified.